Arterial Stiffness and Endothelial Function in Heart Failure (NCT07713719) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Arterial Stiffness and Endothelial Function in Heart Failure
50 participantsStarted 2026-08
Plain-language summary
Heart Failure (HF) is a global condition affecting at least 26 million people worldwide. Despite advances in treatment, HF patients continue to experience poor health outcomes. This study aims to improve understanding of the role of blood vessels in people with heart failure.
The study will assess how arterial stiffness (how stiff blood vessels are) and endothelial function (how well the lining of blood vessels functions) change over time and respond to treatments received as part of routine clinical care. Blood vessel function and heart performance will be assessed at three time points:
* At baseline (when Patients are first diagnosed with heart failure).
* After completing 4 ± 2 weeks of heart-failure medicines prescribed to patients as part of their routine clinical care.
* After completion of cardiac rehabilitation program as a part of their routine clinical care.
All assessments are non-invasive.
Who can participate
Age range
18 Years – 90 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male and female ≥ 18 years old.
* Have a confirmed de-novo diagnosis of Heart failure with preserved ejection fraction or Heart failure with reserved ejection fraction. Common HF phenotypes (e.g., hypertension, diabetes, obesity) will be recorded as part of routine baseline data but will not influence recruitment or sampling. .
* Have stable Heart failure in the opinion of the investigator.
* Have ability, in the opinion of the investigator, to participate in study activities.
* Able to provide written informed consent.
Exclusion Criteria:
* • Inability to provide verbal informed consent.
* Presenting with severe symptoms; major co-morbidity or other alternative diagnoses (e.g., malignancy, severe respiratory disease, severe mental health problem/s).
* Recent acute coronary syndrome (within 60 days).
* Severe physical disability preventing independence.
* Severe renal insufficiency.
* Pregnancy (Present or planned).
* Life expectancy less than 12 months
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in Arterial stiffness measured by Pulse wave velocity (PWV) using SphygmoCor
Timeframe: Up to 12 week
2
Change in Endothelial Function Measured by Laser Doppler Flowmetry (LDF)